Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813496 | 0.91 | ALDH1A1 (0.59) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1813499 | 0.91 | ALDH1A1 (0.59) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1809903 | 0.90 | CCR3 (0.50) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1809902 | 0.90 | CCR3 (0.50) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1812629 | 0.89 | RAB9A (0.47) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1812627 | 0.89 | RAB9A (0.47) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL12625814 | 0.88 | CCR3 (0.53) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1809276 | 0.88 | CCR3 (0.53) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1811204 | 0.88 | CCR3 (0.50) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G | |
| SCHEMBL1811205 | 0.88 | CCR3 (0.50) | CCR3ALDH1A1APOBEC3ANPSR1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CCR3 1/4885ALDH1A1 2661/4885APOBEC3A 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.